Investment expert says Bayer can't prove that glyphosate is not a carcinogen

Below is the summary of an article from an investment expert that is worth reading in full at the URL given, where you can view graphs and illustrations.

Referencing the recent court cases in which cancer sufferers were awarded massive damages against Bayer based on the probability that exposure to Roundup caused their disease, the expert writes, "According to the author's estimates, should Bayer lose just a minority of its cases that are similar to Johnson vs. Monsanto and Pilliod vs. Monsanto in regards to glyphosate causing cancer, the company will potentially face $10.9 billion in implied legal liabilities and be effectively wiped out of its FY 2018 adj. shareholder's equity. In addition, if Bayer was to lose 1.50% of such cases, this may result in liabilities equivalent to its long term debt stack of $42.57 billion."

The take-home message is: "Compensatory and punitive damages ruled against Bayer in less than 1% of its outstanding litigation cases have the potential to wipe out its entire shareholder's equity."
---

Glyphosate's non-carcinogen status unverifiable. Price floor may not exist for Bayer shares

Zhiyuan Sun
SeekingAlpha, Jun 28, 2019
https://seekingalpha.com/article/4272657-glyphosates-non-carcinogen-status-unverifiable-price-floor-may-exist-bayer-shares

Summary

* Bayer does not have a scientific method to definitely prove its innocence in accusations that its best selling herbicide, glyphosate, causes cancer.

* Due to the severity of these allegations, phase 2 and above clinical trials in humans cannot be conducted to evaluate the safety of glyphosate.

* Compensatory and punitive damages ruled against Bayer in less than 1% of its outstanding litigation cases have the potential to wipe out its entire shareholder's equity.